Patient and physician expectations regarding disease and treatment of advanced HCC: The prospective PERCEPTION1 study
Open Access
- 23 August 2024
- journal article
- research article
- Published by Elsevier in JHEP Reports
- Vol. 6 (11) , 101192
Abstract
No abstract availableKeywords
Funding Information
- Ipsen Pharma SAS
This publication has 20 references indexed in Scilit:
- Patient-Reported Outcomes, Tumor Markers, and Survival Outcomes in Advanced GI CancerJAMA Network Open, 2023
- Tremelimumab plus Durvalumab in Unresectable Hepatocellular CarcinomaNEJM Evidence, 2022
- Molecular pathogenesis and systemic therapies for hepatocellular carcinomaNature Cancer, 2022
- Patient-reported outcomes with atezolizumab plus bevacizumab versus sorafenib in patients with unresectable hepatocellular carcinoma (IMbrave150): an open-label, randomised, phase 3 trialThe Lancet Oncology, 2021
- Willingness to bear adversity and beliefs about the curability of advanced cancer in older adultsCancer, 2019
- Patient‐reported outcome measures among breast cancer survivors: A cross‐sectional comparison between Malaysia and high‐income countriesPsycho-Oncology, 2018
- EASL Clinical Practice Guidelines: Management of hepatocellular carcinomaJournal of Hepatology, 2018
- Prevalence of and Factors Related to Discordance About Prognosis Between Physicians and Surrogate Decision Makers of Critically Ill PatientsJAMA, 2016
- Association of Actual and Preferred Decision Roles With Patient-Reported Quality of CareJAMA Oncology, 2015
- “PSA-itis”: Knowledge of Serum Prostate Specific Antigen and Other Causes of Anxiety in Men with Metastatic Prostate CancerJournal of Urology, 2002